Jeffrey S. Rubin, M.D., Ph.D., Scientific Advisor

Dr. Rubin has extensive experience in basic and translational research pertaining to growth control, signal transduction and palliative care in oncology. He obtained his B.A. and M.A. in Chemistry from Harvard University and his M.D. and Ph.D. in Molecular Biology from Washington University in St. Louis. After completion of an Internal Medicine residency training program at the Jewish Hospital in St. Louis, he joined the Laboratory of Cellular and Molecular Biology at the National Cancer Institute. Dr. Rubin spent over 28 years at the NCI, retiring as a Senior Investigator in 2014. He has published over 100 peer-reviewed articles as well as more than 25 reviews, commentaries or book chapters, and is co-inventor on more than 20 patents. He received many federal technology transfer awards, most notably in connection with the development of palifermin (derivative of keratinocyte growth factor), a therapeutic agent that is used to ameliorate severe oral mucositis.